The 2017 Biochemistry Retreat is fast approaching and will be an all day event on Thompson’s Island in Boston Harbor on Friday June 16th.
We hope all members of Biochemistry labs are able to attend and like last year we are looking forward to a great day.
In order to be sure we have enough life jackets (and food) we need to get RSVP’s as soon as possible. Please fill out the form below to let us know if you are able to attend. We will be sending out a separate form to students and postdocs to collect poster titles. If you have any suggestions for the retreat please add them to the form or talk to a member of the retreat committee.
2017 Retreat Committee:
Matt, Bob, Valentina, Erika, Jean, Rekha, Yang
The Schreiber laboratory recently published a paper in PLOS One where they describe a novel mechanism whereby the acute phase protein serum amyloid A regulates extracellular matrix production. This work has relevance to cardiovascular disease including atherosclerosis. Former PhD students Stephanie Seidl and Larry Pessolano are co-first authors on this research.
A new study from the Perissi lab has revealed an unexpected layer of regulation in the insulin signaling cascade based on the opposing actions of the ubiquitin conjugating enzyme Ubc13 and its inhibitor GPS2. The work, recently published in Molecular Metabolism, shows that Ubc13-mediated ubiquitination of the AKT/PKB kinase is required for its phosphorylation and activation in the insulin signaling cascade. Conversely, loss of GPS2-mediated inhibition of Ubc13 activity promotes sustained insulin signaling both in vitro, in 3T3-L1 adipocytes, and in vivo in the adipose tissue of GPS2-AKO mice. Dr. Valentina Perissi and Carly Cederquist, the graduate student who led the project, discuss their finding in the 60 Second Metabolist video (below)
Spurring growth of healthy brown fat with experimental drug
We’re all familiar with white fat—a bit too familiar, perhaps. White fat is the stuff bulging around our waists and thighs, the result of too little exercise and too much fast food. Today, with more than one-third of American adults and 17 percent of children obese, according to the US Centers for Disease Control and Prevention, scientists are scrambling for new ways to treat obesity. One hope stems from a surprising place: brown fat, which is in many ways the alter ego of white.
Brown fat burns glucose and lipids to create heat, and it works in other ways to counter obesity, inflammation, and their ill effects. For many years, scientists thought that brown fat existed only in small mammals and newborn human babies, who need help staying warm. Then, in 2009, scientists found brown fat in adult humans, and suddenly it became one of the hottest topics in metabolism research.
Scientists have since found several ways to coax the growth of brown or “brown-like” fat in mice. The burning questions today: what is the best way to encourage the growth of brown fat, or even better, turn bad white fat into brown? And is there a way to turn this basic science into a drug for humans? If so, it would be the biological equivalent of turning lead to gold.
Now, a team of BU biochemists, led by Stephen Farmer, a School of Medicine professor of biochemistry, and postdoctoral fellow Hong Wang, offers the latest word on brown fat alchemy. In work published December 13, 2016, in Cell Metabolism, the researchers show that treating mice with the experimental chemotherapy drug Roscovitine (also known as Seliciclib or CYC202) produces patches of brown fat within the white, simultaneously increasing the mice’s energy expenditure and improving their metabolism. The group also developed a novel way to sort brown fat cells from white and sequence the cells’ genes. Their work uncovered three genetically distinct forms of brown fat, which they are calling “classic brown,” “beige,” and “brite,” and all of them seem to arise from different pathways. The work is significant because it suggests multiple routes and methods that might encourage brown fat to grow.
“This is a provocative study, which really illustrates that brown and beige fat are druggable targets in a meaningful physiological way,” says Bruce Spiegelman, a Harvard Medical School professor of cancer biology and a leading authority on fat cell regulation and differentiation. “Whether or not Roscovitine should be used is still an open question; it’s a toxic drug—but this study shows that drugs can be used.”
White fat looks white because it’s full of molecules called lipids, usually condensed into one large blob, that the body uses for long-term energy storage. Brown fat has lipids too, but they are broken into many droplets that the cell is constantly burning as fuel. Brown fat looks brown because it is packed with mitochondria, the bean-shaped powerhouses that make ATP (the coenzyme adenosine triphosphate), often called the energy currency of our cells. The mitochondria found in brown fat are a quirky lot, containing a special molecule called uncoupling protein, which allows the mitochondria to slack off on some of their ATP-making duties in favor of generating heat. The presence of this uncoupling protein, along with extra mitochondria and many lipid droplets, is the hallmark of brown fat.
The scientists already knew of two ways to induce the growth of brown fat cells in mice: with a diabetes drug called Avandia or by exposing them to cold—or a drug that mimics the body’s response to cold. In humans, Avandia makes white fat act healthier—producing more beneficial hormones and reducing inflammation. In mice, scientists have also found that the drug encourages patches of brown fat to grow within the white, a process called “beigeing.” But there are side effects: Avandia can cause, paradoxically, weight gain and heart problems in some patients.
“The ideal thing would be to have a drug that does all the good things Avandia does, without the side effects,” says Farmer, senior author on the Cell Metabolism study. “A lot of research now is focusing on what exactly the beigeing fat is, how it functions, and how we can activate it.”
For their current research, Farmer’s team raised two groups of mice, feeding them either a normal diet or a high-fat, high-calorie diet to induce obesity. The mice were further subdivided into groups receiving Avandia, a drug called CL-316,243 that mimics the body’s response to cold, the experimental chemotherapy drug Roscovitine, or nothing. After eight weeks, they found that only Roscovitine produced positive effects like lower blood glucose, less weight gain, and increased beigeing of white fat, with no negative effects like fatty liver deposits.
Next came the genetic analysis. The group used special transgenic mice for the experiment, in which their white fat cells fluoresced red and brown fat cells fluoresced green. This fat cell color-coding allowed the team to separate the brown and white cells and then analyze their genes. The researchers found four very different genetic patterns: one for white fat cells, one for classic brown cells, one for cold-induced brown, or “beige,” cells, and one for Avandia- or Roscovitine-induced brown, or “brite,” cells. It’s not yet clear if the cells have truly distinct origins or simply have different gene programs activated by different drugs. The patterns included a handful of genes not formerly known to be involved with fat.
It’s too early to say whether this work will lead to new treatments for obesity in humans. But Roscovitine, already in phase 2 clinical trials for certain cancers, appears to offer some hope. “This drug has great potential,” Farmer says.
Congratulations to Cathy Costello for her election as an AAAS Fellow. This is a well-deserved recognition of Dr. Costello’s contributions to mass spectrometry, particularly developing and applying new technologies to advance medicine and increase understanding of biology, and for service to the global community.
The Department of Biochemistry, in collaboration with the Genome Science Institute at Boston University School of Medicine is undertaking a major expansion in the areas of Genetics and Genomics. We invite applications at the Assistant, Associate, and Full Professor levels. Several positions are available, and these will be highly competitive with regard to start-up funds, newly renovated space, and salary.
We seek creative scientists using cutting-edge technologies and experimental systems to address important problems in Genetics and Genomics. Areas of interest include, but are not limited to, chromatin structure and function, epigenetics/epigenomics, single-cell genomics, metabolic regulation, control of gene expression, DNA damage and repair, stem cells and development, and cancer genomics. The position requires a Ph.D. or M.D., and relevant postdoctoral experience.
Applicants should submit a cover letter, curriculum vitae, statement of research interests, and list of publications to https://academicjobsonline.org/ajo/jobs/7645.
Letters of recommendation should be provided only if requested by the Search Committee. Applications will be reviewed beginning September 15, 2016, and continuing until the positions are filled. Please direct email queries to email@example.com.
Boston University is an equal opportunity and affirmative action employer.
Dr. Brown and the Provost’s cabinet recently announced that Daniel Cifuentes was awarded the Peter Paul Developmental Professorship. The awards highlight the caliber, potential, and continued vitality of Boston University’s diverse faculty and include a three-year, non-renewable stipend designed to support scholarly or creative work, as well as a portion of the recipients’ salaries. Peter Paul Career Development Professorships are awarded University-wide.
A biochemist and developmental biologist, Daniel Cifuentes’ laboratory examines the early stages of embryo formation and the role of RNA during this period, using research on zebrafish to yield new insights into basic mechanisms of development. He is a graduate of the University of Barcelona (Spain), where he also received his doctorate in Biochemistry. He completed his postdoctoral training at Yale University.
The scientific community has long wondered why some people who are obese develop type 2 diabetes while others do not. A team led by Biochemistry Instructor Libin Liu, PhD, and Professor of Biochemistry and Medicine Paul Pilch, PhD, thinks they are closer at finding out the answer.
Their study, which has appeared in eLife Sciences describes on a protein called PTRF (Cavin-1) inside fat cells. Fat cells normally function to store fat a person ingests. By studying animal models and cells, authors Liu and Pilch conclude that PTRF controls the production of new proteins to allow a fat cell to accommodate more fat. Loss of PTRF results in inefficient fat storage, and dietary fat is mis-targeted to other tissues.
The common Western diet is overly rich in nutrients. The body has to respond to incoming waves of fat by storing them. What distinguishes a “healthy obese” individual from a diabetic obese individual may be the ability of their fat cells to make new fat storage proteins. The latter fails to mount an adequate protein production response in the fat cells, and this leads to fat spilling over to liver and muscle, resulting in type 2 diabetes.
Understanding the role of PTRF may help to clarify how the body distributes fat in health and in disease. Such knowledge may bring new opportunities to treat diabetes in humans. Even as more research unfolds, Liu and Pilch agree that diabetes is a complex condition involving many other proteins, and that “Diet and exercise continue to be the first choice for preventing and treating Type 2 diabetes.”
Submitted by Sherry Yan, MD.
The 2016 Departmental retreat was in early June and took place on Thompson Island in the Boston Harbor. The day was a great success and included rapid faculty talks, round table discussions, a lively poster session, and time to explore the island and relax on the beach.
The Grunebaum Faculty Research Fellowship funded by the Karin Grunebaum Cancer Research Foundation (http://www.grunebaumfoundation.org/) is an annual BUSM faculty award, which provides funds to a selected faculty member for a period of one year. In addition, upon request, the Foundation will provide up to $1,500 for the selected faculty member to travel to seminars and conventions related to their research. The RFA for 2017-2018 will be released in April 2017.
Neil Ganem, Ph.D.
Assistant Professor of Pharmacology and Medicine
Boston University School of Medicine
Mikel Garcia-Marcos, Ph.D.
Assistant Professor of Biochemistry
Boston University School of Medicine